ACADIA Pharmaceuticals Inc. Selling, General and Administrative (SG&A) Expenses Growth

Selling, General and Administrative (SG&A) Expenses Growth of ACAD for past 10 years: annual, quarterly and twelve month trailing (TTM) including Selling, General and Administrative (SG&A) Expenses Growth growth rates and interactive chart.


Highlights and Quick Summary

  • Selling, General and Administrative (SG&A) Expenses Growth for the quarter ending December 30, 2020 was 31.03% (a 99.81% increase compared to previous quarter)
  • Year-over-year quarterly Selling, General and Administrative (SG&A) Expenses Growth increased by 170.3%
  • Annual Selling, General and Administrative (SG&A) Expenses Growth for 2020 was 19.06% (a -16.7% decrease from previous year)
  • Annual Selling, General and Administrative (SG&A) Expenses Growth for 2019 was 22.88% (a 250.38% increase from previous year)
  • Annual Selling, General and Administrative (SG&A) Expenses Growth for 2018 was 6.53% (a -82.25% decrease from previous year)
  • Twelve month Selling, General and Administrative (SG&A) Expenses Growth ending December 30, 2020 was 21.21% (a 12.34% increase compared to previous quarter)
  • Twelve month trailing Selling, General and Administrative (SG&A) Expenses Growth increased by 64.55% year-over-year
Trailing Selling, General and Administrative (SG&A) Expenses Growth for the last four month:
30 Dec '20 29 Sep '20 29 Jun '20 30 Mar '20
21.21% 18.88% 19.72% 12.89%
Visit stockrow.com/ACAD for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Selling, General and Administrative (SG&A) Expenses Growth of ACADIA Pharmaceuticals Inc.

Most recent Selling, General and Administrative (SG&A) Expenses Growthof ACAD including historical data for past 10 years.

Interactive Chart of Selling, General and Administrative (SG&A) Expenses Growth of ACADIA Pharmaceuticals Inc.

ACADIA Pharmaceuticals Inc. Selling, General and Administrative (SG&A) Expenses Growth for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2020 31.03% 15.53% 27.31% 11.48% 19.06%
2019 23.7% 19.0% -2.15% 52.79% 22.88%
2018 11.37% -0.81% 13.66% -7.21% 6.53%
2017 15.65% 21.87% 20.4% 138.84% 36.79%
2016 154.97% 148.84% 140.39% 13.31% 111.15%
2015 117.06% 152.05% 165.58% 283.88% 169.65%
2014 143.66% 112.19% 218.59% 193.82% 157.45%
2013 86.07% 155.69% 60.41% 29.58% 81.74%
2012 55.48% -2.24% -42.98% -11.89% -8.03%
2011 -2.64% -3.74% 75.84% 3.86% 17.77%
2010 -42.46% -20.86% -41.7% -37.15%

Business Profile of ACADIA Pharmaceuticals Inc.

Sector: Healthcare
Industry: Biotechnology
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; Trofinetide, a novel synthetic analog for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor for treating cognition and schizophrenia. It is also developing pimavanserin as a treatment for dementia-related psychosis and as an adjunctive treatment for schizophrenia; and pimavanserin as an adjunctive treatment for major depressive disorder. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.